2-(5-bromo-1H-indol-3-yl)-N-[1-(4-methylphenyl)-2-oxopyrrolidin-3-yl]-2-oxoacetamide
C21H18BrN3O3 — CID 163362077
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-(5-bromo-1H-indol-3-yl)-N-[1-(4-methylphenyl)-2-oxopyrrolidin-3-yl]-2-oxoacetamide
2-(5-bromo-1H-indol-3-yl)-N-[1-(4-methylphenyl)-2-oxopyrrolidin-3-yl]-2-oxoacetamide (PubChem CID 163362077) has the molecular formula C21H18BrN3O3 and a molecular weight of 440.30 g/mol. Its IUPAC name is 2-(5-bromo-1H-indol-3-yl)-N-[1-(4-methylphenyl)-2-oxopyrrolidin-3-yl]-2-oxoacetamide.
Molecular Properties
| Compound Name | 2-(5-bromo-1H-indol-3-yl)-N-[1-(4-methylphenyl)-2-oxopyrrolidin-3-yl]-2-oxoacetamide |
|---|---|
| PubChem CID | 163362077 |
| Molecular Formula | C21H18BrN3O3 |
| Molecular Weight | 440.30 g/mol |
| Exact Mass | 439.05 |
| IUPAC Name | 2-(5-bromo-1H-indol-3-yl)-N-[1-(4-methylphenyl)-2-oxopyrrolidin-3-yl]-2-oxoacetamide |
| SMILES | Cc1ccc(N2CCC(NC(=O)C(=O)c3c[nH]c4ccc(Br)cc34)C2=O)cc1 |
| InChI | InChI=1S/C21H18BrN3O3/c1-12-2-5-14(6-3-12)25-9-8-18(21(25)28)24-20(27)19(26)16-11-23-17-7-4-13(22)10-15(16)17/h2-7,10-11,18,23H,8-9H2,1H3,(H,24,27) |
| InChIKey | FRTCELCKOMDMAN-UHFFFAOYSA-N |
| XLogP | 3.34 |
| TPSA | 82.27 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 440.30 |
| LogP ≤ 5 | 3.34 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 3 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'diketo_group', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 163362077 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.